Miscellaneous
This podcast series is sponsored by Vectra®. Discussion does not constitute or imply endorsement of the product. In this episode, Adam J. Brown, MD, and Jon Giles, MD, explore the history of cardiovascular risk in rheumatoid arthritis from the 1950s onward, including the emergence of data surrounding inflammation and cardiovascular disease, as well as the need for therapeutics that go beyond simply treating joint pain. Intro :11 Intro of Dr. Jon Giles :22 Today’s episode 1:36 How did you become interested in cardiovascular disease in rheumatology? 2:18 When did cardiovascular risk become part of the discussion about RA? 4:33 How to follow patients over time and develop a better sense of cardiovascular risk through studies. 7:23 Are there unique cardiovascular risk factors among RA patients? 10:19 CRP levels as predictive of cardiovascular events 12:09 The biology behind cytokines associated with cardiovascular risk 14:22 Are current interventions and therapeutics making a difference? 16:27 General awareness among patients and physicians of cardiovascular disease and RA 18:29 Roles and responsibilities in cardiovascular risk management 21:15 How do we screen for cardiovascular risk beyond lipid panels? 22:27 Where is the field of cardiovascular risk and RA going? 24:01 Steroids, NSAID’s, and cardiovascular risk 25:43 Episode wrap up 27:04 Thanks for listening 27:49